Mcintyre Freedman & Flynn Investment Advisers Inc Bristol Myers Squibb CO Transaction History
Mcintyre Freedman & Flynn Investment Advisers Inc
- $139 Billion
- Q2 2024
A detailed history of Mcintyre Freedman & Flynn Investment Advisers Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mcintyre Freedman & Flynn Investment Advisers Inc holds 7,052 shares of BMY stock, worth $394,559. This represents 0.21% of its overall portfolio holdings.
Number of Shares
7,052Holding current value
$394,559% of portfolio
0.21%Shares
5 transactions
Others Institutions Holding BMY
# of Institutions
2,454Shares Held
1.5BCall Options Held
29.6MPut Options Held
32.1M-
Vanguard Group Inc Valley Forge, PA187MShares$10.4 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.88 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$5.12 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$4.18 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$3.3 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $119B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...